Infliximab Monotherapy as First-Line Treatment for Hepatic, Splenic, and Pulmonary Sarcoidosis in a Patient With High Cardiometabolic Risk.
- 1Department of Internal Medicine IV, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT.
- 2Department of Internal Medicine, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT.
- 3Department of Internal Medicine IV, Systemic Immune-Mediated Diseases Unit (UDIMS), Hospital Professor Doutor Fernando Fonseca, Amadora, PRT.
Abstract
Glucocorticoids remain the first-line treatment for pulmonary and extrapulmonary sarcoidosis, with anti-tumor necrosis factor-alpha (TNF-α) agents such as infliximab typically reserved as steroid-sparing alternatives or for refractory disease. Data on anti-TNF-α monotherapy as first-line treatment, avoiding glucocorticoid exposure altogether, remain limited to isolated case reports. We report the case of a 46-year-old obese man with hypertension and dyslipidemia who presented with hepatic, splenic, and pulmonary sarcoidosis. Given his cardiometabolic risk profile, glucocorticoids were avoided entirely, and infliximab monotherapy was initiated as first-line treatment, resulting in marked clinical and radiological improvement within seven months. This case suggests that infliximab monotherapy may represent a safe and effective first-line alternative to glucocorticoids in selected patients with multiorgan sarcoidosis and significant cardiometabolic comorbidity.
Related
- Evaluation of Delphi high-resolution computed tomography phenotype classification for treatment-naïve patients with pulmonary sarcoidosis
- Nodular Pulmonary Sarcoidosis with a B-cell Reaction Similar to That of IgG4-related Disease
- Pleuroparenchymal Fibroelastosis Lesion in Explanted Lungs of a Patient with Fibrotic Pulmonary Sarcoidosis
- Expert intuition vs. Algorithmic clustering: Mapping radiological subtypes in pulmonary sarcoidosis
- Effects of mechanical thrombectomy combined with anticoagulation vs anticoagulation monotherapy for acute intermediate-high risk pulmonary embolism: study protocol for a randomized controlled trial (CAPE study, ChiCTR2500095253, https://www.medicalresearch.org.cn/clinicalResearch/researchInfo?id=c57630b7-51ec-4b24-83e1-85b9c0a835d6).
BibTeX
@article{coimbra2026infliximab,
title = {{Infliximab Monotherapy as First-Line Treatment for Hepatic, Splenic, and Pulmonary Sarcoidosis in a Patient With High Cardiometabolic Risk.}},
author = {Matilde Coimbra and Carolina Saca and Maria Carolina Carvalho and Marisa Neves and José Delgado Alves},
journal = {Cureus},
year = {2026},
month = sep,
doi = {10.7759/cureus.116827},
url = {https://europepmc.org/article/MED/42927362},
note = {CC BY},
}
RIS
TY - JOUR
TI - Infliximab Monotherapy as First-Line Treatment for Hepatic, Splenic, and Pulmonary Sarcoidosis in a Patient With High Cardiometabolic Risk.
AU - Matilde Coimbra
AU - Carolina Saca
AU - Maria Carolina Carvalho
AU - Marisa Neves
AU - José Delgado Alves
PY - 2026
DA - 2026/09/24
JO - Cureus
DO - 10.7759/cureus.116827
UR - https://europepmc.org/article/MED/42927362
AB - Glucocorticoids remain the first-line treatment for pulmonary and extrapulmonary sarcoidosis, with anti-tumor necrosis factor-alpha (TNF-α) agents such as infliximab typically reserved as steroid-sparing alternatives or for refractory disease. Data on anti-TNF-α monotherapy as first-line treatment, avoiding glucocorticoid exposure altogether, remain limited to isolated case reports. We report the case of a 46-year-old obese man with hypertension and dyslipidemia who presented with hepatic, splenic, and pulmonary sarcoidosis. Given his cardiometabolic risk profile, glucocorticoids were avoided entirely, and infliximab monotherapy was initiated as first-line treatment, resulting in marked clinical and radiological improvement within seven months. This case suggests that infliximab monotherapy may represent a safe and effective first-line alternative to glucocorticoids in selected patients with multiorgan sarcoidosis and significant cardiometabolic comorbidity.
SN - 2168-8184
ER -